Solventum Corporation (NYSE:SOLV) Given Consensus Rating of "Hold" by Analysts

Key Points

• Solventum Corporation (NYSE:SOLV) has an average analyst rating of "Hold", with one analyst rating it as a sell, four as a buy, and six as a hold.
• The stock's 12-month target price from analysts averages at $85.75, while its recent trading price was $73.46, indicating potential upside.
• In its latest earnings report, Solventum exceeded expectations with $1.69 earnings per share, surpassing the consensus estimate of $1.45, reflecting a year-over-year revenue increase of 3.8%.

Solventum Corporation (NYSE:SOLV - Get Free Report) has received an average rating of "Hold" from the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $85.75.

A number of equities analysts have recently commented on the company. Wall Street Zen upgraded Solventum from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Wells Fargo & Company raised their price objective on Solventum from $75.00 to $79.00 and gave the stock an "equal weight" rating in a report on Friday, August 8th. Morgan Stanley upgraded Solventum from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $80.00 to $103.00 in a report on Tuesday, July 15th. Piper Sandler restated an "overweight" rating and issued a $94.00 price objective (up from $87.00) on shares of Solventum in a report on Friday, August 8th. Finally, KeyCorp assumed coverage on Solventum in a report on Friday, June 6th. They issued a "sector weight" rating on the stock.

Solventum Stock Performance

NYSE SOLV opened at $73.46 on Friday. The business's 50-day moving average price is $73.79 and its 200 day moving average price is $72.87. Solventum has a twelve month low of $59.35 and a twelve month high of $85.92. The company has a market capitalization of $12.74 billion, a PE ratio of 34.01, a price-to-earnings-growth ratio of 1.74 and a beta of 0.52. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14.

Solventum (NYSE:SOLV - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The firm had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.12 billion. During the same period in the prior year, the business posted $1.56 earnings per share. The firm's revenue for the quarter was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, research analysts predict that Solventum will post 6.58 earnings per share for the current year.

Institutional Investors Weigh In On Solventum

Several hedge funds have recently modified their holdings of SOLV. Independent Franchise Partners LLP raised its holdings in shares of Solventum by 74.2% during the 2nd quarter. Independent Franchise Partners LLP now owns 10,141,066 shares of the company's stock valued at $769,098,000 after buying an additional 4,320,342 shares during the period. Norges Bank purchased a new stake in shares of Solventum during the 2nd quarter valued at about $140,495,000. Boston Partners raised its holdings in shares of Solventum by 101.3% during the 1st quarter. Boston Partners now owns 3,361,973 shares of the company's stock valued at $255,554,000 after buying an additional 1,691,565 shares during the period. Trian Fund Management L.P. raised its holdings in shares of Solventum by 18.8% during the 4th quarter. Trian Fund Management L.P. now owns 8,462,819 shares of the company's stock valued at $559,054,000 after buying an additional 1,336,564 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Solventum by 738.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 566,623 shares of the company's stock valued at $43,086,000 after buying an additional 499,031 shares during the period.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.